

Contraction and Relaxation Signaling in Gastrointestinal Smooth Muscle

Othman Abdullah Al-Shboul*

Department of Physiology and Biochemistry, College of Medicine, Jordan University of Science and Technology, Jordan

***Corresponding Author:** Othman Abdullah Al-Shboul, Associate Professor, Department of Physiology and Biochemistry, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.

Received: February 28, 2018; **Published:** April 17, 2018

Abstract

The gastrointestinal (GI) tract is a complex multi-organ system with tissues that differ structurally and functionally. The dynamic interactions between the neuronal, muscular, immune, and glandular tissues allow the GI tract to perform its main physiological functions, which include digestion, absorption, excretion, and protection. Normal gut motility provides for the mixing and propulsion of intraluminal contents to enable efficient digestion of food, progressive absorption of nutrients, and evacuation of residues. These fine and delicate GI tract movements are generated by a highly-regulated interaction between an intricate network of neurons located within the wall of the alimentary canal (i.e. the enteric nervous system), an intrinsic pacemaker system (i.e. interstitial cells of Cajal or ICC) and the final effector cells (i.e. smooth muscle cells). GI tract smooth muscle possesses distinct regional and functional properties that distinguish it from other types of visceral and vascular smooth muscle. Gut smooth muscles contract spontaneously in the absence of neural, humoral, or hormonal stimuli and in response to stretch. They contract as a syncytium (i.e. contract in unison) and therefore classified as unitary type smooth muscle. The molecular mechanisms underlying GI smooth muscle contraction and relaxation signaling pathways are the subject of this review.

Keywords: Smooth Muscle; Contraction; Relaxation; Myosin Light Chain (MLC₂₀); Rho Kinase; MLC Phosphatase

Abbreviations

AMPK: Adenosine Monophosphate Kinase; ATP: Adenosine Triphosphate; CaM: Calmodulin; CaMKII: Calmodulin-Dependent Kinase II; cAMP: Cyclic Adenosine Monophosphate; cGMP: Cyclic Guanosine Monophosphate; CPI-17: PKC Potentiated Inhibitor 17 kDa Protein; GEF: Guanine Nucleotide Exchange Factor; GI: Gastrointestinal; GSNO: S-Nitrosoglutathione; GTP: Guanosine Triphosphate; ICC: Interstitial Cells of Cajal; ILK: Integrin-Linked Kinase; IP3: Inositol Trisphosphate; IP3R: Inositol Trisphosphate Receptor; MLC: Myosin Light Chain; MLCK: Myosin Light Chain Kinase; MLCP: Myosin Light Chain Phosphatase; MRP: Multidrug Resistant Protein; MYPT1: Myosin Phosphatase Target Subunit 1; NO: Nitric Oxide; PACAP: Pituitary Adenylate Cyclase-Activating Peptide; PAK1: p21-Activated Protein Kinase 1; PDE: Phosphodiesterase; PKA: Protein Kinase A; PKC: Protein Kinase C; PKG: Protein Kinase G; PLA2: Phospholipase A2; PLC: Phospholipase C; Ppicδ: Protein Phosphatase Delta Isoform; S1P: Sphingosine-1-Phosphate; sGC: Soluble Guanylate Cyclase; SIP2: Sphingosine 1-Phosphate Receptor 2; ZIPK: Zipper Interacting Protein Kinase

Signaling for smooth muscle contraction

An essential step in smooth muscle contraction is phosphorylation of the 20 kDa regulatory myosin light chain (MLC₂₀) by a Ca²⁺/calmodulin-dependent or -independent myosin light chain kinase (MLCK) which transfers the phosphate group from ATP to either Ser¹⁹ or Thr¹⁸ hydroxyl groups of MLC₂₀. This phosphorylation activates the actin-activated myosin ATPase and actin-myosin interaction, which thereby initiates smooth muscle contraction.

Citation: Othman Abdullah Al-Shboul. "Contraction and Relaxation Signaling in Gastrointestinal Smooth Muscle". *EC Gastroenterology and Digestive System* 5.5 (2018): 315-321.

An increase in intracellular free Ca^{2+} concentration induces activation of Ca^{2+} /CaM-dependent MLCK and the phosphorylation of MLC_{20} and thus muscle contraction. The decrease in intracellular level of Ca^{2+} induces dissociation of the Ca^{2+} -CaM-MLCK complex, resulting in dephosphorylation of the MLC_{20} by myosin light chain phosphatase (MLCP) and thus smooth muscle relaxation [1,2]. Thus, the phosphorylation level of MLC_{20} is determined by the opposing activities of MLCK and MLCP and both of these enzymes' activities are well-regulated in smooth muscle.

MLCK regulation

As mentioned previously, smooth muscle tone is regulated by signaling cascades initiated by enteric neurotransmitters acting directly on smooth muscle receptors. In circular smooth muscle cells, contractile agonists activate PLC- β 1 via $G\alpha_q$ coupled receptors (e.g. muscarinic m3 receptors) by $G\alpha_q$ binding to PLC- β 1's COOH-terminal tail [3]. PLC- β 1 hydrolyzes PIP2 into DAG and IP3. An increase in IP3 leads to the binding of IP3 to the high affinity IP3 receptor/ Ca^{2+} channel on the sarcoplasmic reticulum, resulting in the release of Ca^{2+} into the cytosol. Of the two IP3 receptor isoforms (IP3R-I and IP3R-III) expressed in smooth muscle cells, only IP3R-I mediates Ca^{2+} release [4].

In longitudinal smooth muscle cells, Ca^{2+} mobilization is dependent on a mandatory step involving Ca^{2+} influx via voltage-gated Ca^{2+} channels[4]. Upon contractile agonist stimulation, both G_q - and G_i -coupled receptors activate cytoplasmic PLA2 resulting in phosphatidylcholine hydrolysis into arachidonic acid which induces membrane depolarization and opening of voltage-gated Ca^{2+} channels. The entry of Ca^{2+} stimulates cyclic ADP ribose formation and induces synergistic Ca^{2+} - and cyclic ADP ribose-induced Ca^{2+} release via ryanodine receptors/ Ca^{2+} channels [5].

MLCK activity is strictly dependent on $[Ca^{2+}]_i$ which, upon agonist stimulation, increases as a result of Ca^{2+} influx into the cytosol through voltage-gated channels and/or the release of Ca^{2+} from intracellular stores. Resting levels of $[Ca^{2+}]_i$ (70-100nM) increases up to 8-fold during maximum contraction.

Four Ca^{2+} ions bind to calmodulin (CaM) cofactor which then binds to and activates MLCK [6]. The transient high levels of $[Ca^{2+}]_i$ are then extruded from the cell and/or up taken into the sarcoplasmic Ca^{2+} stores. This decrease in the intracellular level of Ca^{2+} induces dissociation of the Ca^{2+} -CaM-MLCK complex, which thereupon decreases MLCK activity. MLC_{20} phosphorylation and contraction, however, are maintained by Ca^{2+} -independent MLCKs and regulated inhibition of MLCP activity in a process called Ca^{2+} sensitization [1].

Moreover, MLCK activity was shown to be regulated by protein kinases that act to provide negative feedback mechanisms. Stull and coworkers have found that MLCK is phosphorylated by CaMKII, and this phosphorylation decreases the activity of MLCK by decreasing the affinity of the enzyme for calmodulin. It was found that $[Ca^{2+}]_i$ required for the half-maximum activation of CaMKII equals 500 nM, whereas that for MLCK activation is only 250 nM, suggesting a role for CaMKII in inactivation of MLCK when smooth muscle is hyperactivated and $[Ca^{2+}]_i$ rises above some critical level [7]. A similar mechanism has been proposed recently with AMP kinase (AMPK) in which AMPK phosphorylates MLCK at Ser⁸¹⁵ leading to decreased activity of MLCK. It was found that ablation of AMPK augmented contraction, suggesting rapid MLCK attenuation and suppression of contraction by AMPK [8]. In addition, p21-activated protein kinase 1 (PAK1) was shown to attenuate smooth muscle contraction by phosphorylating and inactivating MLCK [9] (Figure 1).




Figure 1: Regulation of MLCK and MLCP by various signaling pathways in the gastrointestinal smooth muscle.

MLCP regulation

While MLCK-mediated contraction is strictly dependent on $[Ca^{2+}]_i$, agonist-induced MLC_{20} phosphorylation and contraction can be maintained even after $[Ca^{2+}]_i$ returns to basal levels via two ways; MLC_{20} phosphorylation by Ca^{2+} -independent MLCKs and regulated inhibition of MLCP (Figure 1).

An important step in maintaining contraction via MLCP inhibition involves activation of RhoA via a cascade leading to sequential agonist-mediated activation of Gq/ $G\alpha_{13}$ and Rho guanine nucleotide exchange factor (Rho-GEF) [9,10]. Activated Rho A (Rho-GTP) is translocated to the plasma membrane where it activates both Rho kinase -mainly Rho kinase II, the predominant smooth muscle isoform- and PLD [11]. Hydrolysis of phosphatidylcholine by PLD yields phosphatidic acid, which is dephosphorylated to diacylglycerol, resulting in sustained activation of Ca^{2+} -dependent and -independent PKC isozymes. Rho kinase and PKC act concurrently and cooperatively to inhibit MLCP activity [2].

The same receptors that initiate Ca^{2+} mobilization and MLCK-mediated MLC_{20} phosphorylation and contraction also engage a distinct G protein-dependent pathway that mediates Ca^{2+} -independent MLC_{20} phosphorylation and contraction via negative regulation of MLCP. Some receptors (e.g. m3 receptors) are coupled to RhoA via G_{13} only, whereas others (e.g. SIP2 and motilin receptors) are coupled to RhoA via both Gq and G_{13} [9,12,13].

Structurally, MLCP holoenzyme consists of three subunits; a 37 kDa catalytic subunit of type 1 phosphatase (ppic δ), a 110 to 130 kDa regulatory subunit, known as myosin phosphatase target subunit I or MYPT1, and a 20 kDa subunit of unknown function. MYPT1 binding to the catalytic subunit enhances MLCP catalytic activity [14].

Phosphorylation of MYPT1 at Thr⁶⁹⁶ by Rho kinase promotes dissociation of the catalytic and regulatory subunits of MLCP and inhibits its catalytic activity [15]. Rho kinase also phosphorylates Thr⁸⁵³ within the myosin-binding domain on MYPT1 upon which the enzyme dissociates from myosin and decreases the efficiency of the enzyme by decreasing availability of the substrate [10]. On the other hand, phosphorylation of an adjacent Ser⁶⁹⁵ by cAMP- or cGMP-dependent protein kinase (PKA and PKG, respectively) blocks the ability of Rho kinase to phosphorylate Thr⁶⁹⁶ and so restores MLCP activity [16].

PKC, mainly PKC- ϵ and PKC- δ , phosphorylates CPI-17, a 17 kDa endogenous inhibitor of MLCP, at Thr³⁸ and greatly enhancing its ability to inhibit MLCP [17]. Thus, a dual Rho-dependent mechanism (i.e. via Rho kinase and PKC activation) causes sustained inhibition of MLCP. The relative involvement of Rho-mediated pathways-Rho kinase/MYPT1 and PKC/CPI-17- in MLCP inhibition appears to be receptor-specific. Most Gq/ G_{13} -coupled receptors (e.g. m3, SIP2, motilin) engage both pathways. ETA receptors engage only Rho kinase/MYPT1 while LPA3 receptors engage only PKC/CPI-17 [12,13,18,19].

Zipper interacting protein kinase (ZIPK) was also found to inhibit MLCP. It is a serine/threonine kinase expressed in various tissues including smooth muscle and is a member of the death-associated protein kinase (DAP) family [20]. ZIPK co-localizes with MLCP and is phosphorylated following activation of Rho kinase-dependent pathway during carbachol stimulation of rabbit bladder. The phosphorylated ZIPK, in turn, phosphorylates the myosin-binding subunit at Thr⁶⁹⁶, considerably faster and even more effective than Rho kinase [21,22]. Niiro and Ikebe, however [23], have demonstrated that MYPT1 is a poor substrate for ZIPK, and instead, ZIPK acts as a Ca^{2+} -independent MLCK that directly phosphorylates MLC_{20} at both Ser¹⁹ and Thr¹⁸ in absence of Ca^{2+} . It has been suggested that the myofilament-bound ZIPK may mediate Rho kinase-dependent phosphorylation of MYPT1 and inhibition of MLCP and thus could be the link between the activated plasma membrane-bound Rho kinase and MYPT1.

Integrin-linked kinase (ILK) is another myofilament-bound Ca^{2+} -independent MLCK. It mediates MLC_{20} phosphorylation, at both Ser¹⁹ and Thr¹⁸, and smooth muscle contraction through Gi-coupled receptors. These receptors sequentially activate ILK through certain pathway involving PI3-kinase activation via G $\beta\gamma$ i [24].

Signaling for relaxation

Smooth muscle relaxation is initiated by targeting MLC_{20} dephosphorylation. This involves either MLCK inactivation and/or removal of MLCP inhibition. Most agents cause relaxation by stimulating the production of cAMP (e.g. VIP and its homologue PACAP) or cGMP (e.g. nitric oxide [NO]) leading to activation of PKA, PKG or both. Cyclic AMP-activated PKA and cGMP-activated PKG are the main enzymes that induce relaxation in smooth muscle. They target different components of the contractile signaling pathways that attenuate MLCK activity and/or augment MLCP activity which eventually induce dephosphorylation of MLC_{20} and thus smooth muscle relaxation [2] (Figure 2).




Figure 2: Regulation of gastrointestinal smooth muscle relaxation by PKA and PKG.

Cyclic nucleotide regulation

The levels of cAMP and cGMP in gastrointestinal smooth muscle depend on the rates of their synthesis by cyclases and degradation by phosphodiesterases (PDEs). Cyclic AMP, which is produced in ~10-fold greater amounts than cGMP, is generated from ATP via the membrane-bound adenylate cyclase (AC) -type V and VI- and is rapidly degraded by the cAMP-preferring PDE3 and cAMP-specific PDE4. On the other hand, cGMP is generated from GTP via the soluble guanylate cyclase (sGC) and is rapidly degraded by cGMP-specific PDE5. PKA inhibits AC while PKG inhibits sGC. Both PDE3 and PDE4 are activated by PKA, but only PDE3 is inhibited by cGMP. On the other hand, PDE5 is activated by PKG. When both cAMP and cGMP are present, PDE5 is also activated by PKA [25-27]. So, regulatory feedback from the protein kinases inhibits synthesis and accelerates degradation, and thereby maintains the levels of cyclic nucleotides within a narrow range.

Although cAMP preferentially activates PKA, it can, at higher concentrations, also cross-reactivate PKG [28]. An increase in both cAMP and cGMP, such as that brought about by corelease of NO, VIP, and PACAP from the same or adjacent nerve terminals, is the physiological norm during nerve-induced relaxation of the gut. Inhibition of PDE3 by cGMP enhances cAMP levels, whereas activation of PDE5 by PKA and PKG greatly increases its affinity for the more abundant cAMP. Under these conditions, PKG is activated by both cGMP and cAMP [27,29].

In addition to degradation by phosphodiesterases, cyclic nucleotides elimination pathways comprise active export into the extracellular space via members of the multidrug resistance protein (MRP) family (the other name is ABC transporters). MRPs bind and hydrolyze ATP, providing the energy to transport their substrates across membrane barriers (Figure 3). Among the MRP family members, MRP4 and MRP5 have been shown to be competent in the transport of cAMP and cGMP respectively [30]




Figure 3: Regulation of cGMP level by phosphodiesterase 5 (PDE5) and multidrug resistance protein (MRP) in the gastrointestinal smooth muscle.

PKA and PKG targets

PKA and PKG indirectly target MLCK inactivation by primarily decreasing $[Ca^{2+}]_i$. Both PKA and PKG can inhibit Ca^{2+} mobilization by inhibiting IP₃ formation in circular muscle and arachidonic acid formation in longitudinal muscle. Inhibition of IP₃ formation in circular muscle involves phosphorylation of RGS4, leading to more rapid degradation of $G\alpha_q$ -GTP and inhibition of PLC- β 1 activity. PKG-mediated phosphorylation of SERCA2 and sarcoplasmic reticulum IP₃ receptors accelerates Ca^{2+} reuptake into the stores and inhibits IP₃-induced Ca^{2+} release, respectively. In addition, both kinases inhibit the activity of membrane Ca^{2+} channels and stimulate the activity of membrane K^+ channels, leading to hyperpolarization of the plasma membrane and interruption of Ca^{2+} influx into the cell, a mechanism that is important in relaxation of rhythmic contraction[2].

Moreover, PKG and PKA augment MLCP activity by different ways; first, they phosphorylate the activated form of RhoA (Rho-GTP) at Ser¹⁸⁸ leading to its inactivation and translocation back to the cytosol [31]. Second, both enzymes can phosphorylate MYPT1 at Ser⁶⁹⁵, preventing the inhibitory regulation of Rho kinase-mediated phosphorylation of MYPT1 at Thr⁶⁹⁶ [16]. Finally, both kinases are able to phosphorylate (at Ser¹³) and enhance the activity of telokin, a smooth muscle-specific endogenous activator of MLCP [32].

Conclusion

Phosphorylation of ML_{20} is an essential step in GI smooth muscle contraction. Contractile agonists increase MLC_{20} phosphorylation by Ca^{2+} /CaM-dependent stimulation of MLCK and RhoA-dependent inhibition of MLCP activity. Relaxant agonists decrease MLC_{20} phosphorylation either by decreasing Ca^{2+} levels or increasing MLCP activity via PKA and PKG-dependent pathways. Better understanding of contraction and relaxation signaling pathways in the GI smooth muscle in different physiological and pathophysiological states will help in designing more effective drugs for treating various GI contractile diseases.

Acknowledgements

The author thanks Dr. Murthy Karnam from Virginia Commonwealth University for helping in drawings and providing insight and expertise that greatly assisted the research. Thanks for Jordan University of Science and Technology for support.

Conflict of Interest

The author declares any conflict of interest.

Bibliography

1. Somlyo A and AV Somlyo. "Signal transduction and regulation in smooth muscle". *Nature* 372.6503 (1994): 231-236.
2. Murthy KS. "Signaling for contraction and relaxation in smooth muscle of the gut". *Annual Review of Physiology* 68 (2006): 345-374.
3. Rhee SG. "Regulation of phosphoinositide-specific phospholipase C". *Annual Review of Biochemistry* 70 (2001): 281-312.
4. Murthy KS., et al. "InsP3-dependent Ca²⁺ mobilization in circular but not longitudinal muscle cells of intestine". *American Journal of Physiology* 261 (1991): G937-G944.
5. Kuemmerle JF., et al. "Longitudinal smooth muscle of the mammalian intestine. A model for Ca²⁺ signaling by cADPR". *Cell Biochemistry and Biophysics* 28.1 (1998): 31-44.
6. Kamm KE and JT Stull. "Dedicated myosin light chain kinases with diverse cellular functions". *Journal of Biological Chemistry* 276.7 (2001): 4527-4530.
7. Tansey MG., et al. "Ca²⁺-dependent phosphorylation of myosin light chain kinase decreases the Ca²⁺ sensitivity of light chain phosphorylation within smooth muscle cells". *Journal of Biological Chemistry* 269.13 (1994): 9912-9920.
8. Horman S., et al. "AMP-activated protein kinase phosphorylates and desensitizes smooth muscle myosin light chain kinase". *Journal of Biological Chemistry* 283.27 (2008): 18505-18512.
9. Murthy KS., et al. "Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway". *Biochemical Journal* 374.1 (2003): 145-155.
10. Somlyo A and AV Somlyo. "Ca²⁺ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase". *Physiological Reviews* 83.4 (2003): 1325-1358.
11. Murthy KS., et al. "Sequential activation of heterotrimeric and monomeric G proteins mediates PLD activity in smooth muscle". *American Journal of Physiology-Gastrointestinal and Liver Physiology* 280.3 (2001): G381-G388.
12. Huang J., et al. "Signaling pathways mediating gastrointestinal smooth muscle contraction and MLC20 phosphorylation by motilin receptors". *American Journal of Physiology-Gastrointestinal and Liver Physiology* 288.1 (2005): G23-G31.
13. Zhou H and KS Murthy. "Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2". *American Journal of Physiology-Cell Physiology* 286.5 (2004): C1130-C1138.
14. Hartshorne DJ., et al. "Myosin light chain phosphatase: subunit composition, interactions and regulation". *Journal of Muscle Research and Cell Motility* 19.4 (1998): 325-341.

15. Fukata Y, *et al.* "Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells". *Trends in Pharmacological Sciences* 22.1 (2001): 32-39.
16. Wooldridge AA, *et al.* "Smooth muscle phosphatase is regulated in vivo by exclusion of phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine 695 in response to cyclic nucleotides". *Journal of Biological Chemistry* 279.33 (2004): 34496-34504.
17. Murthy KS, *et al.* "Sustained muscle contraction induced by agonists, growth factors, and Ca(2+) mediated by distinct PKC isozymes". *American Journal of Physiology-Gastrointestinal and Liver Physiology* 279.1 (2001): G201-G210.
18. Hersch E, *et al.* "Gq/G13 signaling by ET-1 in smooth muscle: MYPT1 phosphorylation via ETA and CPI-17 dephosphorylation via ETB". *American Journal of Physiology-Cell Physiology* 287.5 (2004): C1209-C1218.
19. Zhou HJ and Murthy KS. "Lysophosphatidic acid (LPA) interacts with LPA3 receptors to activate selectively Gαq and induce initial and sustained MLC20 phosphorylation and contraction". *Gastroenterology* 126 (2004): A278.
20. Shani G, *et al.* "Death-associated protein kinase phosphorylates ZIP kinase, forming a unique kinase hierarchy to activate its cell death functions". *Molecular and Cellular Biology* 24.19 (2004): 8611-8626.
21. MacDonald JA, *et al.* "Identification of the endogenous smooth muscle myosin phosphatase-associated kinase". *Proceedings of the National Academy of Sciences of the United States of America* 98.5 (2001): 2419-2424.
22. Borman MA, *et al.* "Smooth muscle myosin phosphatase-associated kinase induces Ca²⁺ sensitization via myosin phosphatase inhibition". *Journal of Biological Chemistry* 277.26 (2002): 23441-23446.
23. Niiron N and M Ikebe. "Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle contraction via myosin light chain phosphorylation". *Journal of Biological Chemistry* 276.31 (2001): 29567-29574.
24. Murthy KS, *et al.* "Receptors coupled to inhibitory G proteins induce MLC20 phosphorylation and muscle contraction via PI3-kinase-dependent activation of integrin-linked kinase (ILK)". *Gastroenterology* 126 (2004): A413.
25. Francis SH, *et al.* "Cyclic nucleotide phosphodiesterases: relating structure and function". *Progress in Nucleic Acid Research and Molecular Biology* 65 (2001): 1-52.
26. Murthy KS. "Activation of phosphodiesterase 5 and inhibition of guanylate cyclase by cGMP-dependent protein kinase in smooth muscle". *Biochemical Journal* 360.1 (2001): 199-208.
27. Murthy KS, *et al.* "PKA-dependent activation of PDE3A and PDE4 and inhibition of adenylyl cyclase V/VI in smooth muscle". *American Journal of Physiology-Cell Physiology* 282.3 (2002): C508-C517.
28. Murthy KS and GM Makhlof. "Interaction of cA-kinase and cG-kinase in mediating relaxation of dispersed smooth muscle cells". *American Journal of Physiology* 268 (1995): C171-C180.
29. Murthy KS. "cAMP inhibits IP(3)-dependent Ca(2+) release by preferential activation of cGMP-primed PKG". *American Journal of Physiology-Gastrointestinal and Liver Physiology* 281.5 (2001): G1238-G1245.
30. Ritter CA, *et al.* "Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5)". *Drug Metabolism Reviews* 37.1 (2005): 253-278.
31. Murthy KS, *et al.* "Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA". *American Journal of Physiology-Gastrointestinal and Liver Physiology* 284.6 (2003): G1006-G1016.
32. MacDonald JA, *et al.* "Phosphorylation of telokin by cyclic nucleotide kinases and the identification of in vivo phosphorylation sites in smooth muscle". *FEBS Letters* 479.3 (2000): 83-88.

Volume 5 Issue 5 May 2018

©All rights reserved by Othman Abdullah Al-Shboul.